Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2009-02-23 Director's Dealing
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
MAIN DOCUMENT DESCRIPTION
Director's Dealing
2009-02-23 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations release announcing the European Commission approval for a biosimilar filgrastim by Sandoz, a division of Novartis. The document is primarily a press release providing regulatory approval news and business update rather than a financial report or detailed financial data. It does not contain financial statements or detailed financial analysis. It is not an annual or interim report, earnings release, or management discussion. It is a regulatory announcement about a product approval and business development. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2009-02-17 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content is an investor relations press release announcing that Novartis has gained worldwide rights to a Phase II anti-clotting compound, elinogrel, including details of the licensing agreement, clinical trials, and financial terms. There are no financial statements or detailed financial performance data included. The document is primarily an announcement of a business development and licensing agreement, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit other specific categories.
2009-02-13 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains an investor relations release about clinical study results for the drug Zometa, including detailed study data and safety information. The document is not an annual report, audit report, earnings release, or any other specific financial report. It is a regulatory filing used by foreign companies to report material information to the SEC between annual reports. The length is about 15,000 characters, and the content is primarily an announcement of clinical study results and related information, typical of a 6-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2009-02-13 English
6-K
Annual Report Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to SEC rules. The content includes a detailed group review, financial highlights, business segment performance, corporate citizenship, governance, remuneration report, and consolidated financial statements. The document covers the full fiscal year 2008 and includes comprehensive financial data, management discussion, and operational review. The length is substantial (15,000 characters), and it contains actual financial statements and analysis rather than just an announcement or certification. The presence of consolidated financial statements and detailed operating and financial review indicates this is an Annual Report equivalent filing for a foreign issuer, which corresponds to the 10-K category in our classification system.
2009-02-09 English
SC 13G/A
Major Shareholding Notification
2009-02-09 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.